Jump to content

Publication: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group

From CAMIH
Revision as of 08:03, 26 June 2024 by MKraft (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


Reference
Title Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group
Topic Vitamin B6
Author Newling, D, Robinson, M, Smith, P, Byar, D, Lockwood, R, Stevens, I, De Pauw, M, Sylvester, R
Year 1995
Journal European urology
DOI https://doi.org/10.1159/000475139

Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.

This double-blind randomised phase III trial was designed to assess the effect of pyridoxine administration on the recurrence ofTa and T1 transitional cell tumours ofthe bladder. The trial accrued 291 patients and showed no significant difference between the pyridoxine and placebo treatment groups with respect to the time to first recurrence or the recurrence rate. Adjustment for the main prognostic factors, namely the recurrence rate prior to entry, the number of tumours at entry, the G grade and the levels of the tryptophan metabolites kynurenine plus acetyl kynurenine at entry do not change the overall conclusions.



This publication is referenced in the following studies:

  1. Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group